CDK7/9-IN-1 is acyclin-dependent kinases7/9 (CDK7/9) inhibitor. CDK7/9-IN-1 selectively inhibitsCDK7overCDK9. CDK7/9-IN-1 inhibitsCDK7withIC₅₀s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibitsCDK9with anIC₅₀of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research ofcancer^[1].

CDK7/9-IN-1 (example 8; 0.001-20 μM; 4 h) inhibits CDK7 with an relative IC₅₀of 0.0262 μM for phospho-carboxyl terminal domain (Rbp2) (Ser5) in HCT116 cells^[1].
CDK7/9-IN-1 (0.001-20 μM; 4 h) inhibits CDK9 with an IC₅₀of 2.59 μM for phospho-carboxyl terminal domain (Rbp2) (Ser2) in HCT116 cells^[1].
CDK7/9-IN-1 (0.001-20 μM; 4 h) inhibits cMyc with an relative IC₅₀of 0.0138 μM in HCT116 cells^[1].
CDK7/9-IN-1 (20 μΜ, 2 μΜ, and 0.2 μΜ; 1 h) shows excellent selectivity against the 468 protein kinases panel. CDK7/9-IN-1 shows approximately 96% inhibition against CDK7^[1].

479.54

C₂₄H₃₂F₃N₅O₂

2747919-19-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.